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Urine and plasma levels of uroguanylin and its molecular forms
in renal diseases
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Urine and plasma levels of uroguanylin and its molecular forms in
renal diseases. Uroguanylin activates the intestinal and possibly the renal
guanylate cyclase C receptor, and stimulates C1 secretion. We developed
a sensitive radioimmunoassay (RIA) for human uroguanylin and mea-
sured its concentration in the urine and plasma. Twenty-four-hour urinaly
excretion of immunoreactive (ir-) uroguanylin for persons with a high-salt
diet (10 glday) was 137.8 14.4 pmol/day, significantly higher than that
for persons with a low-salt diet (7 glday, 95.1 16.3 pmol/day, P < 0.05).
There were significantly positive correlations between the urinary excre-
tion of ir-uroguanylin and Na, Cl, K or cyclic GMP (cGMP). We
demonstrated the presence of messenger RNA of guanylate cyclase C in
the medulla of human kidney. The concentration of plasma ir-uroguanylin
significantly correlated with that of serum creatinine (r = 0.71, P < 0.001).
Biologically active uroguanylin-16 accounted for 99% of the endogenous
uroguanylin molecules in normal urine and 60% in plasma, the remainder
being the 10 kDa precursor. The precursor content increased in the urine
and plasma as the severity of renal impairment increased. These findings
suggest that bioactive uroguanylin-16 is involved in the regulation of
electrolyte homeostasis and that the kidney participates in the metabolism
and excretion of uroguanylin.
Uroguanylin, a 16-amino acid peptide recently isolated from
human and opossum urine, shares 50% amino acid sequence
homology with guanylin [1, 2]. These two peptides enhance cyclic
GMP (cGMP) production by activating the transmembrane guan-
ylate cyclase C receptor (GC-C), thereby stimulating Cl secre-
tion by means of the cystic fibrosis transmembrane conductance
regulator protein (CFTR) [3, 4]. Heat-stable enterotoxins (ST5),
which comprise 15 to 30 amino acid peptides, have high degrees of
structural homology with uroguanylin and guanylin and act on
intestinal GC-C by molecular mimicry, causing secretory diarrhea.
The proximal tubules of opossum kidney have apical membrane
receptors that bind 1251-labeled STs [5]. STs increase the cGMP
contents in opossum renal slices and cultured opossum kidney
cells [6]. STs administered intravenously or intramuscularly elicit
large increases in the cGMP concentration of opossum urine [5,
6]. Administration of STs to perfused rat kidney decreases
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fractional sodium transport in the proximal tubules [7]. CFTR
also is abundant in the apical membrane of the tubular cells [8, 9].
These results suggest the existence of a GC-C ligand in the kidney.
Recently, Forte et al hypothesized that uroguanylin acts as an
intestinal natriuretic hormone influencing salt and water ho-
meostasis through an endocrine axis between the intestine and the
kidney [10], because it is abundant in urine [1, 2]. However,
Northern analysis showed that uroguanylin messenger RNA
(mRNA) is expressed in the intestine, but not in the kidney [11,
12]. Using a sensitive radioimmunoassay (RIA) for human bioac-
tive uroguanylin [13], we examined the effects of changes in
dietary salt intake on the urine excretion of immunoreactive (ir-)
uroguanylin and studied the relationships between the urine
excretion of uroguanylin and Nat, K, C1 and cGMP. We also
determined the plasma concentration of ir-uroguanylin in normal
individuals and in patients with various degrees of renal impair-
ment, and identified the endogenous molecular forms of urogua-
nylin in their plasma and urine. Finally, we have shown for the first
time the existence of mRNA for GC-C in the medulla of human
kidney by the reverse transcription-polymerase chain reaction
(RT-PCR), thus confirming the ligand/receptor system.
METHODS
Peptides
Human bioactive uroguanylin and Tyr°-uroguanylin were syn-
thesized by the solid phase method with an ABI 430A or 433A
peptide synthesizer. Human bioactive uroguanylin and generated
Tyr°-uroguanylin were isolated by reversed-phased high perfor-
mance liquid chromatography (RP-HPLC) [14]. Synthetic Tyr°-
uroguanylin was radioiodinated by the lactoperoxidase method.
Radloimmunoassay procedure
Antiserum was raised in rabbits against synthetic bioactive
human uroguanylin conjugated with bovine thyroglobulin as pre-
viously reported [13]. The bioactivity of the uroguanylin and the
guanylin molecules was confirmed by their production of cGMP in
T84 human colon cancer cells that express GC-C. The RIA
incubation buffer was 0.05 M sodium phosphate (pH 7.4) that
contained 0.25% bovine serum albumin (BSA) treated with
N-ethylmaleimide, 0.08 M NaCl, 0.025 M EDTA 2Na, 0.05%
NaN3, and 0.1% Triton X-100. The diluted sample or a standard
peptide solution (100 .tl) was incubated with 100 .d of the
antiserum diluent (final dilution 1/20,000) for 24 hours. One
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hundred microliters of 1251-labeled ligand (16,000 cpm) then were
added, and the mixture was incubated for 24 hours. The bound
and free ligands were separated with a polyethylene glycol solu-
tion. All procedures were conducted at 4°C. Samples were assayed
in duplicate.
Quantification of immunoreactive uroguanylin
Urine. Twenty-four-hour urine samples were obtained from the
following groups: 19 controls who had no signs of heart failure,
renal diseases or gastrointestinal diseases (8 men and 11 women;
mean age SEM, 59.5 3.7 years); 13 patients with chronic
glomerulonephritis (CGN patients; 3 men and 10 women; mean
age, 47.8 5.8 years) whose serum creatinine levels were  1.0
mg/dl; 13 patients with chronic renal failure (CRF patients; 10
men and 3 women; mean age, 51.6 5.8 years) whose serum
creatinine levels were  1.5 mg/dl (3.0 0.8 mg/dl); and 12
patients on maintenance hemodialysis (HD patients; 9 men and 3
women; mean age, 58.9 5.7 years). Renal biopsies of the CGN
patients showed that 6 had membranous giomerulopathy, 3 minor
glomerular abnormalities, 2 IgA nephropathy, and 2 lupus nephri-
tis. The underlying diseases of the CRF patients were chronic
glomerulonephritis in 7, hypertension in 3, collagen disease in 2
and amyloidosis in 1. Those of the HD patients were hypertension
in 5, chronic glomerulonephritis in 4, diabetes mellitus in 2 and
medullary cystic disease in 1. Twenty-eight subjects (19 controls
and 9 CGN patients without nephrotic syndrome) were divided
into groups with a high-salt diet (10 g/day, 2 men and 10 women;
mean age, 53.5 4.2 years) and a low-salt diet (7 g/day, 6 men and
10 women; mean age, 53.9 5.8 years). The subjects in both
groups had been on "low" or "high" salt diets for more than three
days. The urine specimens were centrifuged at 3,000 rpm for 15
minutes at 4°C. The supernatant was diluted by one half with 0.9%
saline and applied to a Sep-Pak C-18 cartridge (Waters Associ-
ates, Milford, MA, USA) that had been equilibrated with 0.9%
saline, after which the cartridge was washed with saline and 10%
acetonitrile (CH3CN) solution containing 0.1% trifluoroacetic
acid (TFA). Peptides were eluted with 60% CH3CN solution
containing 0.1% TFA. The eluate was used for the RIA. The urine
Na, K, C1, creatinine and cGMP concentrations were also
measured in 18 different patients, and plasma atrial natriuretic
peptide (ANP) and brain natriuretic peptide (BNP) values were
measured in 16 of the 18 patients whose serum creatinine levels
were 1.O mg/dl; patients with nephrotic syndrome, gastrointes-
tinal diseases and congestive heart failure were excluded. These
patients were allowed free diet selection. The plasma ANP and
BNP concentrations were measured with specific immunoradio-
metric assays for human ANP and BNP (ShionoRlA kits,
Shionogi Co., Osaka, Japan).
Plasma. The subjects comprised four groups: 13 normal indi-
viduals (7 men and 6 women, mean age 27.7 0.95 years); 12
CGN patients whose serum creatinine levels were  1.0 mg/dl and
crcatinine clearance levels  80 mI/mm (3 men and 9 women,
mean age 32.8 5.1 year, serum creatinine 0.7 0.1 mg/dl); 15
CRF patients whose serum creatininc levels were  1.5 mg/dl (7
men and 8 women, mean age 56,9 3.8 years, serum creatinine
5.2 0.8 mg/di); and 10 hemodialysis (HD) patients (2 men and
8 women, mean age 52.6 5.3 years). Blood was taken from the
CGN and CRF patients after an overnight fast and from the HD
patients just before the beginning of HD. Blood was drawn into
chilled polypropylene tubes containing EDTA 2Na (1 mg/mi of
blood) and aprotinin (500 units/mi of blood) and immediately
centrifuged at 3,000 rpm for 15 minutes at 4°C. The supernatant
was diluted to one half with 0.9% saline and applied to a Sep-Pak
C-18 cartridge as described above. The eluate was used for the
RIA.
Characterization of immunoreactive uroguanylin in urine and
plasma
Urine was obtained from 3 normal controls, 3 CGN patients
(serum creatinine < I mg/di), 3 moderate CRF patients (serum
creatinine 2 to 4 mg/di), and 3 HD patients. Plasma was obtained
from these same individuals. The urine and plasma samples were
applied to individual Sep-Pak C-18 cartridges as described above.
The eluates from the cartridges were subjected to RP-HPLC on a
TSK ODS SIL 120 A column (4.6 )< 150 mm). A 10% to 60%
linear gradient of CH3CN in 0.1% TFA was run for 40 minutes at
a flow rate of 1.0 mi/minute. RIA was used to quantify the
uroguanyiin content of each fraction. Synthetic human bioactive
uroguanyiin was chromatographed under the same conditions.
The ir-fractions, #41 to 43 in Figure 6C, were analyzed by gei
permeation chromatography on a TSK gel G2000 SW column
under the conditions described in the legend to Figure 6D.
Human uroguanylin and rat 10-kDa proguanylin purified from rat
intestine [151 aiso were chromatographed under the same condi-
tions.
RT-PCR
Total RNA was extracted from human renal medulla and
cortex, and colon by the acid guanidinium thiocyanate-phenol-
chloroform method [161. To digest the genomic DNA, 3 units of
RNase-free DNase I (Pharmacia, Uppsaia, Sweden), 110 U of
RNase inhibitor, 40 mrvi Tris-HC1 (pH 7.6) and 6 mM MgCI2 were
added to the 2.5 gg RNA samples. The samples then were
incubated for 30 minutes at 37°C, after which they were heated to
90°C for five minutes to inactivate the DNase. The sequences and
names of primers used in the RT-PCR assay are given in Table 2.
The first strand of eDNA was synthesized with 0.4 j.g of an RNA
sample that had been treated with DNase, 2.5 j.LM GCC-ASI
primer, a dNTP mixture (1 mM each), 110 U of RNase inhibitor
and 200 U of reverse transcriptase (GIBCO BRL, Gaithersburg,
MD, USA). Reverse transcription was conducted for 30 minutes
at 42°C followed by incubation for three minutes at 94°C to
inactivate the reverse transcriptase. The resulting eDNA was
subjected to PCR amplification with 2 /.tM GCC-S and GCC-ASI
primers, and 1.25 U of Taq DNA polymerase (Perkin-Elmer
Cetus, Norwalk, CT, USA). The reaction volume was 25 gl, and
the PCR conditions were 35 cycles of denaturation for 30 seconds
at 94°C, annealing for 30 seconds at 51°C and extension for 60
seconds at 72°C. Nested PCR was conducted with 1 /LI of the
first-step RT-PCR product and 2 p.M GCC-S and GCC-AS2
primers under the PCR conditions described above. The PCR
products were clectrophoresed on a 2% agarose gci (FMC
BioProducts, Rockiand, ME, USA). Human -actin was used as a
positive control for RT-PCR as described elsewhere [16].
Statistical analysis
Data are expressed as means SE. Simpie linear regression
analysis was used for the correiations. The unpaired Student's
t-test was used for the comparisons of the two randomized groups.
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Table 1. Plasma and urine concentrations of immunoreactive
uroguanylin
Control CON CRF HD
Urine 103.1 15.9 137.6 34.0 196.2 343C 632.8 273.Ia
pmoi/day N = 19 N = 13 N = 13 N = 12
Plasma 5.0 0.3 7.5 0.8" 44.3 121h 216.9 66.4'
final/mi N = 13 N = 12
—
N 15 N= 10
-
C < 0.05, "P < 0.01, P < 0.001 compared with control
Nucleotide number
Primer name Oligonucleotide sequence in [171
Differences were considered significant if the P value was less than
0.05.
RESULTS
When the antiserum was used at the final dilution of 1/20,000,
bioactive uroguanylin was measurable at a minimal concentration
of 0.4 fmol/tube (10% replacement), and the half-maximum
inhibition on the standard RIA curve was 4 fmol/tube (Fig. 1).
The antiserum showed no cross-reactivity with human guanylin.
Twenty-four-hour urinary excretions of ir-uroguanylin of the CRF
and HD patients were significantly higher than the control value
(Tables 1 and 2). The daily excretion of ir-uroguanylin was
significantly higher in the high-salt group than in the low-salt
group (137.8 14.4 pmol/day vs. 95.1 16.3 pmol/day, respec-
tively, P < 0.05; Fig. 2). The daily urine excretions of Na', K and
Cl - in the high-salt group were 143.1 29.7 mEq/day, 36.3 6.2
mEq/day and 142.8 25.5 mEq/day, and those in the low-salt
group were 93.3 14.7 mEq/day, 32.2 6.7 mEq/day and 99.8
19.5 mEq/day, respectively. The urinary excretions of Na ,
and CL significantly correlated with that of ir-uroguanylin (Fig.
3). The urinary excretion of cGMP also significantly correlated
with that of ir-uroguanylin (r = 0.78, P < 0.01). The plasma
concentrations of ANP and BNP were 22.5 5.4 pg/mI and
13.5 5.1 pg/ml, and did not significantly correlate with the
urinary excretion of Nat, K and CL, but did correlate signifi-
cantly with the urinary excretion of cGMP (ANP, r = 0.71, P <
0.05; BNP, r 0.50, P < 0.05).
The plasma ir-uroguanylin concentrations of the CGN, CRF
and HD patients were significantly higher than the control value
(Table 1). The plasma ir-uroguanylin concentrations of the CGN
and CRF patients ranged from 3.5 to 168.2 fmol/ml and correlated
with their serum creatinine concentrations (r = 0.71, P < 0.001;
Fig. 4).
Uroguanylin molecules in human urine and plasma were ana-
lyzed by RP-HPLC coupled with RIA. Representative RP-HPLC
profiles of the molecules in the urine are shown in Figure 5.
Uroguanylin immunoreactivity in samples from controls and CON
patients (Fig. 5A) was detected only at the elution position of
uroguanylin-l6 (fractions #24 and #25). Two major immunore-
0
E
>C
0)0
C
active peaks were found in patients with moderate CRF, one at
the elution position of uroguanylin-16 and the other in fractions
#41 to 43 (Fig. SB). The HD patients showed a major peak at
fractions #41 to 43 and a very minor peak in fractions #24 and
#25 (Fig. SC).
About 60% of the uroguanylin immunoreactivity in normal
plasma was detected at the elution position ot uroguanylin-16
(#24 and #25) and the rest in fractions #41 to 43 (Fig. 6A). The
major peak of immunoreactivity in the plasma from patients with
CGN or HD was in fractions #41 to 43, and there was a very
minor peak, which corresponded to uroguanylin-16, in fractions
#24 and #25 (Fig. 6B and C). To further characterize the
uroguanylin-immunoreactive peptide from fractions #41 to 43
(Fig. 6C), we estimated its molecular weight by gel permeation
chromatography. The peptide was cluted at a position identical to
— — —
1/4 1/2 1
— —
Table 2. Primers for RT-PCR of GC-C
GCC-S 5'-ITCAAATGCACAACGGATGG-3' 375-394
0CC-AS1 5 '-TCCTCCAAGTACTGGTCATF-3' 877-896
GCC-AS2 5'-CGOTCACCCTrCAGC1TGTA-3' 814-833
GCC-S is a sense primer and GCC-AS1 and -AS2 are antisense primers.
100 101 102 io io4
100
50
10
0
Peptide, fmol/tube
Fig. 1. Standard RIA curve for human bioactive uroguanylin. Inhibition
of '251-Tyr°-human bioactive uroguanylin binding to antiserum by serial
dilution of human uroguanylin (0), human guanylin (s), plasma extract
from a CRF patient (z±), and urine extract from a control subject (LI). The
unity scale under the plasma dilution curve represents 20 ,.d and that
above the curve for urine indicates 4 d.
200 P<0.05
150
Fig. 2. Daily excretion of immunoreactive (ir-) uroguanylin for the
groups with high-salt (10 glday) and low-salt (7 glday) diets. Values are
expressed as mean SE.
50
0
NaCI log NaCI 7g
(N=12) (N=16)
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Fig. 3. Correlation between the urine excretion of ir-uroguanylin and
Na (A; r = 0.71; P < 0.0), K (B; r = 0.56; P < 0.05), and Cl (C; r =
0.71; P < 0.001) in 18 patients with normal renal function. Patients with
nephrotic syndrome, gastrointestinal diseases and heart failure were
excluded.
that of rat 10-kDa proguanylin (Mr 10.4 k; Fig. 6D). The
plasma concentrations of bioactive uroguanylin-16 were calcu-
lated from the RP-HPLC findings. The mean concentrations were
3.1 fmol/ml in the controls, 1.9 fmol/mI in the CON patients, 5.9
fmol/ml in the CRF patients, and 29.1 fmol/ml in the HD patients.
GC-C gene expression in human kidney and colon was exam-
ined by RT-PCR using nested PCR. A GC-C transcript product
corresponding to the predicted size was detected at 459 bp in the
renal medulla and colon, but not in the renal cortex (Fig. 7).
An intestinal sensory mechanism for sodium that controls renal
sodium excretion may exist because oral salt loads stimulate
urinary sodium excretion more rapidly than intravenous salt load
[18, 19]. When dietary sodium chloride is low, the regulation of
salt homeostasis is maintained by mineralocorticosteroids under
the influence of the renin-angiotensin pathway. The maintenance
of homeostasis during the intake of high sodium chloride is not
likely to be accomplished simply by turning off the aldosterone
stimulus, ANP is known to be an important hormone in the
control of sodium balance. Ingestion of a high-salt meal elicited a
rapid increase in urinary sodium excretion, but plasma ANP levels
did not increase for seven hours [20], whereas continuous inges-
tion of high-salt meals for 4 or five days elicited a significant
increase in the plasma ANP level [21, 22]. It was suggested that
ANP contributed to the increase in renal sodium excretion when
the high sodium diet was continued for several days, but the
postprandial increase in urinary excretion did not seem to be
mediated by ANP [201. Uroguanylin activates the receptor-gua-
nylate cyclase effector molecules found on the apical membranes
of human T84 intestinal cells and was originally isolated from
opossum and human urine [1, 2]. Two research groups recently
reported that human uroguanylin mRNA is expressed in the
stomach and intestine, but not in the kidney [11, 121. Human
uroguanylin therefore is presumably produced in the gastrointes-
tinal tract and then enters the circulatory system, reaching its
receptors on renal tubular cells via glomerular filtration. We
showed that urinary excretion of ir-uroguanylin was quite large
and that hioactive uroguanylin-16 is abundant in control urine,
suggesting that uroguanylin functions as a hioactive peptide in the
kidney. We also demonstrated an increased excretion of urinary
ir-uroguanylin in the group with a high-salt diet compared with a
low-salt group and found a significant correlation between the
urine excretion of ir-uroguanylin and Na , K, Ci and cGMP.
Plasma levels of ir-ANP and ir-BNP significantly correlated with
A
.
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Fig. 4. Correlation between plasma immunoreactive (ir-) uroguanylin
and serum creatinine concentrations in 27 patients with proteinuria of
more than 300 mg/day (CGN and CRF patients; r = 0.71; P < 0.001).
DISCUSSION
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a different mechanism of action for uroguanylin, independent of
60 GC-C, could be considered. There are reports that cGMP analogshad little effect on Cl uptake by T84 cells and failed to activate
10 CFTR CL channels [26, 27] and STs could stimulate phospho-
i lipase C activity in the intestine [28]. We now have found the
) mRNA of GC-C in the renal medulla. The medulla is composed
of various portions of the nephron and each segment has a unique
transport function. Henle's loop contributes greatly to the urinary
concentration system by the passive transport of NaC1 and water.
Outer and inner medullary collecting ducts are important for the
final regulation of urinary NaCI and water. Taken together with
the significant correlation between the excretion of uroguanylin
60 and cGMP in the urine, the presence of GC-C transcripts in thekidney will further support the notion that uroguanylin acts in the
10 kidney via cGMP mediation. We did not find mRNA of GC-C in
i the cortex. This uneven distribution of GC-C may be one of the
reasons why GC-C has not as yet been identified in the kidney.
Z More detailed investigations, including determining the distribu-
tion of GC-C in the kidney and administration of uroguanylin to
the renal artery, are needed to confirm the activity and mechanism
_______________________________________
of uroguanylin as a local regulator of electrolytes in the kidney.
We have shown significant increases in 24-hour urinary excre-
tion of ir-uroguanylin in patients with CRF and HD. However, the
60 urine concentration of bioactive uroguanylin-16, determined by
RP-HPLC, decreased as residual renal function decreased. A
10 eDNA encoding a precursor for human uroguanylin has been
cloned and sequenced from the human colon eDNA library [11,
12]. On the basis of the human uroguanylin eDNA sequence, it is
predicted that a 10-kDa prouroguanylin will be secreted after
cleavage of a signal peptide in the 112-amino acid preprourogua-
nylin. The major immunoreactive uroguanylin molecule in the
plasma of CGN and CRF patients was the 10-kDa uroguanylin
precursor. Recently, chymotiypsin-like protease within renal tu-
bules has been proposed to activate prouroguanylin through
cleavage of the peptide bond [29]. These findings suggest that the
kidney is the target organ where the uroguanylin precursor is
processed into its active form and that this processing is impaired
in CRF patients.
We found a close correlation between the plasma levels of
ir-uroguanylin and serum creatinine in patients with various
degrees of renal dysfunction. The kidney is important in the
elimination and metabolism of circulating proteins that are
smaller than albumin. These low molecular weight proteins are
extensively filtered in the glomerulus, absorbed by the tubular
epithelium, and eventually hydrolyzed to their constituent amino
acids within the renal cells [30]. We reported that most of the
ir-guanylin in human plasma is the 10 kDa precursor [31] and that
there is an excellent correlation between the plasma levels of
ir-guanylin and serum creatinine [32]. The 10-kDa uroguanylin
precursor found in this study must be filtered in the glomerulus
and absorbed by the tubules of the normal kidney. Obviously, the
decreased filtration of this precursor in CRF patients contributes
greatly to the increased plasma peptide levels. We cannot exclude
the possibility that uroguanylin production is enhanced in order to
increase the urinary excretion of electrolytes, because the plasma
concentration of ir-uroguanylin in CGN patients with normal
renal function was significantly higher than that in the controls.
We demonstrated a greater uroguanylin excretion in patients
with a high-sodium diet than in those with a low-sodium diet as
well as a significant correlation of the excretion of Na, K, CL
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Fig. 5. Representative RP-HPLC profiles of uroguanylin immunoreactiv-
ity in urine. (A) Sample: 1 ml of urine from a CGN patient (serum
creatinine 0.8 mg!dl and creatinine clearance 91 mI/minute). (B) Sample:
1 ml of urine from a CRF patient (serum creatinine 3.2 mg/dl and
creatinine clearance 26 mI/minute). (C) Sample: 1 ml of urine from an HD
patient (serum creatinine 10.1 mg/dl before HD). HPLC was performed
with a TSK ODS SIL 120 A column (4.6 X 150 mm). A linear gradient of
CH3CN from 10% to 60% in 0.1% TFA was run for 40 minutes at a flow
rate of 1.0 mI/mm. Each fraction volume was 0.5 ml. Black bars show
uroguanylin immunoreactivity. Arrows indicate the elution positions of
human uroguanylin-l6 (1) and 10 kDa uroguanylin (2).
the urinary excretion of cGMP, but not with the excretion of Na1,
K and CL. When a high-salt diet is present, ANP seems to be
partly responsible for the natriuresis [21, 22], but one or more
natriuretic factors that relate to an intestinal sensory mechanism
for salt are required [18—201. Uroguanylin may be a candidate for
an intestinal natriuretic factor because it is primarily synthesized
in the intestine.
Activation of the tubular receptors by E. coli ST caused a
marked increase in the urinary excretion of both Na and K [7].
1251-lahelcd STs were bound in the apical membrane receptors of
the proximal tubules of opossum kidney [5]. These studies
strongly indicate the existence of GC-C in the kidney. However,
GC-C has not been rigorously identified in the kidney [23—251 and
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Fig. 7. Electrophoretic analysis of RT.PCR products of human GC-C
and -actin transcripts in the renal medulla and cortex and the colon.
and cGMP with ir-uroguanylin, thus suggesting that uroguanylin
acts as a regulator of the metabolism of these electrolytes in the
kidney. We also demonstrated the presence of niRNA of GC-C in
Abbreviations used in this paper are: ir-uroguanylin, immunorcactive
uroguyanylin; GC-C, guanylate cyclase C; CFFR, cystic fibrosis transmcm-
brane conductance regulator protein; mRNA, messenger RNA; S1s, heat
stable enterotoxins; RIA, radioimmunnassay; RP-HPLC, reversed-phased
high performance liquid chromatography; CGN, chronic glomerulonc-
phritis; PCR, reverse-transcription-polymerase chain reaction; AN?, atrial
natriuretic peptide; BNP, brain natriuretic peptide.
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Fig. 6. Representative RP-HPLC (A, B, C) and gel permeation chromatography (D) profiles of uroguanylin immunoreactivity in plasma. (A) Sample:
27 ml of plasma collected from 3 normal controls. (B) Sample: 24 ml of plasma collected from 3 CGN patients with normal renal function. (C) Sample:
1 ml of plasma from an HD patient. HPLC was performed with a TSK ODS SIL 120 A column (4.6>< 150mm). A linear gradient of 10% to 60% CH3CN
in 0.1% TFA was run for 40 minutes at a flow rate of 1.0 mI/mm. Each fraction volume was 0.5 ml. Black bars show uroguanylin immunoreactivity.
Arrows indicate the elution positions of human uroguanylin-16 (1) and rat 10 kDa proguanylin (2). (D) Sample: fractions #41 to 43 in Figure 6C. Gel
permeation chromatography was performed with a TSK gel G2000 SW column (7.5 x 600 mm). Each fraction volume was 0.5 ml. Peptides were eluted
with 50% CH3CN in 0.1% TFA at a flow rate of 0.5 mI/mm. Black bars show uroguanylin immunorcactivity. Arrows indicate the elution positions of
human uroguanylin-16 (Mr = 1.7 kDa) and rat 10 kDa proguanylin (Mr = 10.4 kDa).
the kidney, confirming the renal action of uroguanylin. We found
that uroguanylin and its precursor circulate in the bloodstream
and that the uroguanylin precursor is increased in CGN and CRF
Medulla Cortex Colon patients. Uroguanylin-16 was the main molecular form of urinary
ir-uroguanylin in the controls and in CGN patients, but it de-
creased as renal failure progressed. These findings lead us to
speculate that the kidney has an important function in the
cleavage and elimination of uroguanylin. More detailed investi-
gations of uroguanylin should furnish new insights into the
regulation of electrolyte homeostasis.
Reprint requests to Tanenao Eta, M.D., First Department of Internal
Medicine, Miyazaki Medical College, 5200 Kihara, Kiyotake, Ttuiyazaki
889-16, Japan.
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